Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Full-year 2025 preliminary 1 U.S. net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026 Strong EMPAVELI ® (pegcetacoplan) launch in C3G and primary IC-MPGN continues,